<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1211246210
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TOBRADEX EYE OINT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOBRAMYCIN,DEXAMETHASONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.3,0.1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ocular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye ointment
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tube
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        20.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="S.A. Alcon Couvreur N.V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            S.A. Alcon Couvreur N.V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01CA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>TOBRADEX is a medicine against certain eye inflammations. It contains:</p><p>&middot;&nbsp;&nbsp;&nbsp; dexamethasone, a strong corticosteroid (substance that can suppress inflammatory reactions)</p><p>&middot;&nbsp;&nbsp;&nbsp; tobramycin, an antibiotic of the aminoglycoside class.</p><p>&nbsp;</p><p>This medicine is used for the treatment of eye inflammations that are sensitive to corticosteroids where there is also a bacterial infection or the risk of a bacterial infection exists, in adults and children aged 2 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>a. </strong><strong>Do not use TOBRADEX</strong></p><p>&middot;&nbsp;&nbsp; If you are allergic (hypersensitive) to tobramycin, dexamethasone or any of the other ingredients of TOBRADEX. These ingredients can be found in section 6.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to aminoglycosides</p><p>&middot;&nbsp;&nbsp; If you think you have an eye infection caused by a virus (such as herpex simplex keratitits, smallpox or chickenpox/ herpes zoster), a fungus or certain bacteria (such as tuberculosis bacteria) or a parasite.If you have an injury or infection limited to the eye surface.</p><p>&middot;&nbsp;&nbsp; After removal of a foreign body from the eye.</p><p>&nbsp;</p><p><strong>b. </strong><strong>Take special care with TOBRADEX</strong></p><p>&middot;&nbsp;&nbsp; Only use TOBRADEX in your <strong>eyes</strong>.</p><p>&middot;&nbsp;&nbsp; <strong>Do not use this medicine without close medical supervision.</strong></p><p>&middot;&nbsp;&nbsp; Steroids applied to the eye may delay the healing of your <strong>eye wound</strong>. Topical NSAIDs (Non-Steroidal Anti Inflammatory Drugs Medications) are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you are <strong>hypersensitive</strong> to <strong>aminoglycosides</strong>, the class of antibiotics to which TOBRADEX belongs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience allergic reactions with TOBRADEX, discontinue use and consult your doctor. Allergic reactions may vary from localized itching or skin redness to severe allergic reactions (anaphylactic reaction) or serious skin reactions. These allergic reactions may occur with other topical or systemic antibiotics of the same family (aminoglycosides)</p><p>&middot;&nbsp;&nbsp; If your <strong>symptoms do not improve</strong>, or <strong>get worse or suddenly return</strong>, please consult your doctor. You may become more susceptible to eye infections with the use of this product.</p><p>&middot;&nbsp;&nbsp; If you are using another antibiotic treatment, with TOBRADEX, ask your doctor for advice.</p><p>&middot;&nbsp;&nbsp; If you have or if you have ever had conditions such as myasthenia gravis or Parkinson&rsquo;s disease, ask your doctor for advice. Antibiotics of this kind may worsen muscle weakness.</p><p>&middot;&nbsp;&nbsp; If you have<strong> glaucoma </strong>(an eye disease caused by an elevated pressure in the eye), your eye pressure should be checked weekly by your doctor.</p><p>&middot;&nbsp;&nbsp; If you have been treated or are being treated for an<strong> eye infection caused by the herpes virus</strong>, using this medicine may reactivate or worsen your infection. Your eyes should be checked regularly by your doctor.&nbsp;</p><p>&middot;&nbsp;&nbsp; If you have a<strong> </strong>disorder causing<strong> a thinning of the eye tissues</strong> (cornea or sclera), ask your doctor or pharmacist for advice before using this medicine. This medicine may cause a perforation of the eyeball.</p><p>&middot;&nbsp;&nbsp; The risk of high pressure inside the eye and/or formation of cataracts (clouding of the lens in the eye) is increased in predisposed patients (for example, diabetes)</p><p>&middot;&nbsp;&nbsp; <strong>In case of prolonged use </strong>(10 days or longer):<strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Your eye pressure should be checked regularly by your doctor. This medicine may increase your eye pressure and may cause glaucoma or cataract (clouding of the eye lens).</p><p>&middot;&nbsp;&nbsp;&nbsp; You may become more susceptible to eye infections.</p><p>&middot;&nbsp;&nbsp;&nbsp; This medicine may decrease the natural production of the hormone cortisol and in this way cause particular diseases or slow the growth rate in children, especially with high-doses or long-term treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp; Develop Cushing&rsquo;s syndrome due to the medicine getting into your blood. Talk to your doctor if you experience swelling and weight gain around the trunk and in the face as these are usually the first manifestations of a syndrome called Cushing&rsquo;s syndrome. Suppression of the adrenal gland function may develop after stopping a long-term or intensive treatment with TOBRADEX. Talk to your doctor before stopping the treatment by yourself. These risks are especially important in children and patients treated with a drug called ritonavir or cobicistat.</p><p>&middot; &nbsp;&nbsp;Contact your doctor if you experience blurred vision or other visual disturbances.</p><p>&middot;&nbsp;&nbsp; <strong>Do not wear contact lenses</strong> (hard or soft) during treatment of an eye inflammation or eye infection. If you are using other medicines, please also read the section &ldquo;Other medicines and TOBRADEX&rdquo;.</p><p>&middot;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;</p><p>Consult your doctor if one of the above warnings is applicable to you or has been in the past.</p><p>&nbsp;</p><p><strong>c. </strong><strong>Children</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TOBRADEX may be used in children aged 2 years and older.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intraocular pressure should be checked frequently, especially in children below 6 years of age receiving dexamethasone-containing products, as the risk of corticosteroid-induced ocular hypertension may be greater in children and may occur earlier than in adults. Ask your doctor for advice especially in children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not give TOBRADEX to children below 2 years old because the safety and efficacy in this population have not been established.</p><p>&nbsp;</p><p><strong>d. </strong><strong>Using other medicines, herbal or dietary supplements.</strong></p><p>If you are using other eye preparations, you must wait at least 5 minutes between each application. Administer your eye ointment last.</p><p>&nbsp;</p><p>Please tell your doctor or pharmacist if you are using have recently used or might use any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>Especially tell your doctor if you are using NSAIDs. Concomitant use of topical steroids and topical NSAIDs may increase corneal healing problems.</p><p>&nbsp;</p><p>Tell your doctor if you are using ritonavir or cobicistat, as this may increase the amount of dexamethasone in the blood.</p><p>&nbsp;</p><p>When using pupil-dilating eye drops, which may cause an increase in pressure inside the eye, using TOBRADEX at the same time may lead to an additional increase in pressure inside the eye</p><p>&nbsp;</p><p><strong>e. </strong><strong>Using TOBRADEX with food and drink</strong></p><p>Food and drink have no influence on your treatment.</p><p>&nbsp;</p><p><strong>f.&nbsp; </strong><strong>Pregnancy and breast-feeding</strong></p><p>TOBRADEX is not recommended during pregnancy or breastfeeding.</p><p>&nbsp;</p><p>If you want to get pregnant, if you are pregnant or if you are breast-feeding, contact your doctor or pharmacist before using any medicine.</p><p>&nbsp;</p><p><strong>g. </strong><strong>Driving and using machines</strong></p><p>If your vision becomes temporarily blurred after using TOBRADEX, do not drive or use machines until your vision has become clear again.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use TOBRADEX exactly as your doctor or pharmacist has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>Your doctor will tell you how long you should use TOBRADEX. <strong>Do not stop the treatment early.</strong></p><p>&nbsp;</p><p><strong>If your symptoms do not improve, or if they get worse or suddenly return, please consult your doctor.</strong></p><p>&nbsp;</p><p><strong>The recommended dose in adults and children aged 2 years and older:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Apply 1 to 1,5 cm &lsquo;ribbon&rsquo; of ointment into your eye, up to 3 or 4 times daily.</p><p>&middot;&nbsp;&nbsp;&nbsp; TOBRADEX eye ointment can be used at bedtime, while the eye drops can be used during the day.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Instructions for use:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
   left:0;text-align:left;margin-left:11.1pt;margin-top:16pt;width:73.5pt;
   height:46.5pt;z-index:251658240' fillcolor="window">
   <v:imagedata src="file:///C:/Users/khalian2/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.wmz"
    o:title=""/>
   <w:wrap type="square"/>
  </v:shape><![if gte mso 9]><o:OLEObject Type="Embed" ProgID="Word.Picture.8"
   ShapeID="_x0000_s1026" DrawAspect="Content" ObjectID="_1653833747">
  </o:OLEObject>
 <![endif]><![endif]--></p><p><img src="data:image/png;base64,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" alt="" width="622" height="200" vspace="0" hspace="0" border="0" style="width:622px;height:200px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>1.&nbsp;&nbsp;&nbsp; <strong>Wash your hands</strong> before using TOBRADEX.</p></td></tr></tbody></table><p>2.&nbsp;&nbsp;&nbsp; Sit down in front of a mirror, so that you can see what you are doing.</p><p>3.&nbsp;&nbsp;&nbsp; Twist off the tube cap.</p><p>4.&nbsp;&nbsp;&nbsp; <strong>Make sure the tube tip touches nothing else</strong>, as this may contaminate the contents.</p><p>5.&nbsp;&nbsp;&nbsp; Tilt your head back.</p><p>6.&nbsp;&nbsp;&nbsp; Pull down the lower eyelid of the affected eye with a finger until there is a &quot;pocket&quot; between the eyelid and the eye (Picture 1). The ointment ribbon must go here.</p><p>7.&nbsp;&nbsp;&nbsp; Bring the tube tip close to your eye. Use the mirror if it helps.</p><p>8.&nbsp;&nbsp;&nbsp; Don&#39;t touch your eye or eyelid, surrounding areas or other surfaces with the tube tip.</p><p>9.&nbsp;&nbsp;&nbsp; Gently squeeze the tube to expel the ointment ribbon into the &quot;pocket&quot; (Picture 2).</p><p>10.&nbsp; <strong>Close your eye for a few seconds</strong> after putting the ointment into your eye (Picture 3).</p><p>11.&nbsp; Repeat steps 6 through 10 for your other eye, if necessary. Close the tube cap firmly.</p><p>&nbsp;</p><p><strong>a. </strong><strong>If you use more TOBRADEX than you should</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have applied more TOBRADEX <strong>into your eye</strong> than necessary, rinse it out from your eye with lukewarm water. Do not put in any more ointment until it is time for your next dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have accidentally <strong>swallowed</strong> TOBRADEX, immediately seek advice from your doctor, pharmacist.</p><p>&nbsp;</p><p><strong>b. </strong><strong>If you forget to use TOBRADEX</strong></p><p>Administer the forgotten dose as soon as possible. <strong>However, do not use a double dose to make up for the missed dose.</strong> If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.</p><p>&nbsp;</p><p><strong>c. </strong><strong>If you stop using TOBRADEX</strong></p><p>A flare-up of your inflammation or infection may occur if you stop the treatment <strong>prematurely</strong>. <strong>Do not suddenly stop using this product without your doctor&rsquo;s advice.</strong> Your doctor may want you to gradually reduce the amount you are using to reduce the chance of side effects.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, TOBRADEX can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The side effects have been grouped according to their frequency of occurrence: <strong>&ldquo;very common&rdquo;</strong>: affect more than 1 in 10 patients, <strong>&ldquo;common&rdquo;</strong>: 1 to 10 in 100 patients, <strong>&ldquo;uncommon&rdquo;</strong>: 1 to 10 in 1000 patients, <strong>&ldquo;rare&rdquo;</strong>: 1 to 10 in 10000 patients, <strong>&ldquo;very rare&rdquo;</strong>: less than 1 in 10000 patients and <strong>&ldquo;not known&rdquo;</strong>: cannot be estimated from the available data.</p><p>&nbsp;</p><p><strong>Stop using this medicine and consult your doctor if you have hypersensitivity reactions</strong>, such as eyelid itching, eye swelling or eye redness.<strong> </strong></p><p>&nbsp;</p><p>The following side effects have been seen with TOBRADEX:</p><p>&middot;&nbsp;&nbsp; <strong>Eye disorders:</strong></p><p>-&nbsp;&nbsp;&nbsp; <strong>Uncommon:</strong> increased eye pressure &ndash; eye pain &ndash; eye itching &ndash; eye discomfort &ndash; eye irritation.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Rare:</strong> eye inflammation &ndash; eye allergy - y &ndash; blurred vision &ndash; dry eye &ndash;&ndash; eye redness.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Not known:</strong> eyelid swelling &ndash; eyelid redness - dilatation of the pupil &ndash; increased tear production &ndash; ulcerative keratitis.</p><p>&middot;&nbsp;&nbsp; <strong>Reactions in other parts of your body:</strong></p><p>-&nbsp;&nbsp;&nbsp; <strong>Rare:</strong> bad taste.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Not known:</strong> severe allergic reaction (hypersensitivity) &ndash; dizziness - headache &ndash;nausea &ndash; abdominal discomfort &ndash; serious skin reactions (erythema multiforme &nbsp;&ndash; swelling of the face &ndash; itching &ndash; redness of the skin</p><p>&nbsp;</p><p>Effects in other parts of your body are not likely because the ocular dose is so much lower than the dose used by mouth or by injection, but some medication can get into your bloodstream. Aminoglycosides administered by mouth or by injection can harm the kidneys or the nerves in your ear.</p><p>&nbsp;</p><p>TOBRADEX contains both tobramycin and dexamethasone. The following side effects have been observed with the individual components of this medicine during ocular use, and may occur with TOBRADEX:</p><p>&middot;&nbsp;&nbsp; <strong>Eye disorders: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Uncommon: </strong>eye irritation - eye redness - blurred vision - increased eye pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Rare: </strong>eye infection - reduced or disturbed vision - glaucoma - cataract - eyelid swelling - eyelid itching -eye pain - damage to the optic nerve.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Very rare: </strong>perforation of the eyeball.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Unknown:</strong> Blurred vision</p><p>&middot;&nbsp;&nbsp; <strong>Reactions in other parts of your body:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Uncommon: </strong>hypersensitivity.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Rare: </strong>impaired healing.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Very rare: </strong>adrenal suppression.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Unknown:</strong> Hormone problems: growth of extra body hair (particularly in women), muscle weakness and wasting, purple stretch marks on body skin, increased blood pressure, irregular or missing periods, changes in the levels of protein and calcium in your body, stunted growth in children and teenagers and swelling and weight gain of the body and face (called &lsquo;Cushing&rsquo;s syndrome&#39;) (see section 2, &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not store above 25&deg;C. Do not refrigerate.</p><p>&nbsp;</p><p><strong>Do not use TOBRADEX longer than 4 weeks after first opening.</strong></p><p>&nbsp;</p><p>Do not use TOBRADEX after the expiry date which is stated on the tube and carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are tobramycin (3 mg/g) and dexamethasone (1 mg/g).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are anhydrous chlorobutanol, liquid paraffin and white soft paraffin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                TOBRADEX eye ointment is a white to off-white, homogeneous ointment, supplied in a 3.5g aluminium tube with a screw cap.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 08/2019 by Belgian health authorities
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL">يُعد عقار توبراديكس دواءً مضادًّا لأنواع معينه من التهابا ت العين. يحتوي على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديكساميثازون، أحد الكورتيكوستيرويدات القوية (مادة يمكنها كبت التفاعلات الالتهابية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توبراميسين، مضاد حيوي من فئة الأمينُوجْليكُوزيدات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم هذا الدَّواء لعلاج التهابات العين الحساسة تجاه الكورتيكوستيرويدات؛ حيث يوجد أيضًا إصابة بعدوى بكتيرية أو يوجد خطر الإصابة بعدوى بكتيرية في البالغين والأطفال من عمر عامين فأكثر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تستخدم عقار توبراديكس</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية &quot;حساسية مفرطة&quot; تجاه توبراميسين, أو ديكساميثازون أو أيٍّ من مكونات عقار توبراديكس الأخرى.&nbsp; يمكن العثور على هذه المكونات في قسم 6.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه الأمينُوجْليكُوزيدات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعتقد أن لديك عدوى بالعين ناجمة عن أحد الفيروسات (مثل الهربس البسيط التهاب القرنية، مرض الجدري أو الجدري المائي/ الهربس النطاقي)، أو الفطريات أو بعض البكتيريا (مثل بكتيريا السل) أو أحد الطفيليات. إذا كان لديك إصابة أو عدوى مقتصرة على سطح العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد إزالة جسم غريب من العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم عقار توبراديكس إِلَّا في <strong>عينيك</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يحظر استخدام هذا الدَّواء بدون إشراف طبي دقيق.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يُؤخر استعمال الستيرويدات في العين التئام جرح العين لديك. يُعرف أيضًا عن مضادات الالتهاب غير الستيرويدية الموضعية (عقاقير- علاجات) بأنها تبطئ أو تؤخر الشفاء. يمكن للاستخدام المتزامن لمضادات الالتهاب غير الستيرويدية الموضعية والستيرويدات الموضعية أن يزيد احتمالية حدوث مشاكل في الشفاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت تعاني من<strong> فرط الحساسية</strong> تجاه <strong>الأمينُوجْليكُوزيدات</strong>، فئة المضادات الحيوية التي ينتمي إليها عقار توبراديكس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تفاعلات حساسية تجاه عقار توبراديكس، فتوقف عن استخدامه واستشر طبيبك. قد تتباين تفاعلات الحساسية من الحكة الموضعية أو احمرار الجلد إلى تفاعلات حساسية شديدة (التفاعل التَّأَقِيّ) أو تفاعلات جلدية خطيرة. قد تحدث تفاعلات الحساسية هذه مع المضادات الحيوية الموضعية أو الجهازية الأخرى من نفس المجموعة (الأمينوجليكوزيدات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا <strong>لم تتحسن الأعراض</strong> لديك أو <strong>تفاقمت </strong>أو <strong>عادت فجأة</strong>، فيُرجى استشارة طبيبك. قد تصبح أكثر عرضة لعدوى العين مع استخدام هذا المنتج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تستخدم علاجات بمضادات حيوية أخرى، بما في ذلك المضادات الحيوية التي تُعطى عن طريق الفم، مع عقار توبراديكس، فاستشر طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تعاني أو عانيت في السابق من حالات الوهن العضلي (ميسثينيا غريفيس) أو مرض الشلل الرعاش (باركنسون)، استشر طبيبك حيث أن المضادات من هذا النوع قد تؤدي لتفاقم الضعف العضلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من<strong> الجلوكوما (المياه الزرقاء)</strong> (مرض بالعين ينجم عن ارتفاع الضغط في العين)، يجب قياس ضغط العين لديك أسبوعيًّا من قبل طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عُولجت أو يتم علاجك من <strong>عدوى بالعين ناجمة عن فيروس الهربس،</strong> قد يُؤدي استخدام هذا الدَّواء إلى إعادة تنشيط أو تفاقم العدوى. يجب فحص عينيك بانتظام من قبل طبيبك.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك اضطراب يُسبب&nbsp; ترققًا في أنسجة العين (القرنية أو الصلبة) فاستشر طبيبك أو الصيدلي الخاص بك قبل استخدام هذا الدَّواء. قد يُسبب هذا الدَّواء انثقاب مقلة العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يزداد خطر الإصابة بارتفاع الضغط داخل العين و/ أو تكوين المياه البيضاء (اعتمام العدسة بالعين) في المرضى ممن هم عرضة للإصابة (على سبيل المثال، مرض السُّكَّرِي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>في حالة الاستخدام لمدة طويلة</strong> (10 أيام أو أكثر):<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب قياس ضغط العين لديك بانتظام من قبل طبيبك.&nbsp;&nbsp; قد يُؤدي هذا الدَّواء إلى ارتفاع ضغط العين لديك وقد يُسبب الجلوكوما (المياه الزرقاء) أو المياه البيضاء (إعتام عدسة العين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصبح أكثر عرضة لعدوى العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يخفض هذا الدَّواء من الإفراز الطبيعي لهرمون الكورتيزول، وبهذه الطريقة تسبب الإصابة بأمراض معينة أو تبطئ معدل النمو لدى الأطفال، وخاصة مع الجرعات العالية أو العلاج طويل الأمد.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصاب بمتلازمة كوشينج نظرًا لوصول الدَّواء إلى الدَّم لديك. تحدَّث إلى طبيبك إذا عانيت من التَّورم وزيادة الوزن حول الجذع وفي الوجه؛ إذ تكون عادةً هذه الأعراض الأولى لمتلازمة تدعى متلازمة كوشينج. قد تصاب بكبت وظيفة الغدة الكظرية بعد وقف العلاج طويل الأمد أو المكثف بعقار توبراديكس. تحدَّث إلى طبيبك قبل إيقاف العلاج من تلقاء نفسك. تُعد هذه المخاطر هامَّة لا سيما في الأطفال والمرضى ممن يتم علاجهم بعقار يُسمى ريتونافير أو كوبيسيستات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بطبيبك إذا عانيت من عدم وضوح الرؤية أو غيرها من اضطرابات الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا ترتدي العدسات اللاصقة</strong> (الصلبة أو اللينة) أثناء علاج التهاب أو عدوى العين. إذا كنت تستخدم أدوية أخرى، يُرجى أيضًا قراءة قسم &quot;استخدام أدوية أخرى مع عقار توبراديكس&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك إذا كان ينطبق عليك، أو قد انطبق عليك في الماضي أي من التحذيرات أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن استخدام عقار توبراديكس في الأطفال بعمر عامين فأكثر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب فحص الضَّغط داخل العين بصورة متكررة، لا سيما في الأطفال تحت سن 6 سنوات ممن يتلقون منتجات دوائية تحتوي على ديكساميثازون؛ إذ قد يكون خطر ارتفاع ضغط العين الذي تحفزه الكورتيكوستيرويدات أكبر في الأطفال وقد يحدث في وقت أقصر من وقت حدوثه لدى البالغين. يُرجى استشارة طبيبك لا سيما في الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تعطِ عقار توبراديكس للأطفال الذين تقل أعمارهم عن عامين؛ لأنه لم يتم التَّحقق من أمان العقار وفعاليته في هذه الفئة من المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وعقار توبراديكس</strong></p><p dir="RTL">إذا كنت تستخدم مستحضرات أخرى للعين، يجب عليك الانتظار لمدة 5 دقائق على الأقل بين كل دواء والآخر. يكون مرهم العين آخر ما يتم استخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيَّة أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على وجه الخصوص، أخبر طبيبك إذا كنت تستخدم مضادات الالتهاب غير الستيرويدية. يمكن للاستخدام المتزامن للستيرويدات الموضعية مع مضادات الالتهاب غير الستيرويدية الموضعية أن يزيد من حدوث مشكلات التئام القرنية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تستخدم عقار ريتونافير أو كوبيسيستات؛ إذ قد يزيد هذا من كمية ديكساميثازون في الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند استخدام قطرات العين الموسعة لحدقة العين، والتي قد تُسبب ارتفاع في الضَّغط داخل العين، قد يُؤدي استخدام عقار توبراديكس في نفس الوقت إلى زيادة إضافية في الضَّغط داخل العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام عقار توبراديكس مع الأغذية والمشروبات</strong></p><p dir="RTL">ليس للأغذية والمشروبات أي تأثير على العلاج الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا يُوصى باستخدام عقار توبراديكس أثناء الحمل أو الرضاعة الطبيعيَّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أردتِ الحمل، أو إذا كنتِ حاملًا أو إذا كنتِ مرضعًا، فاتصلي بطبيبك أو الصيدلي الخاص بكِ قبل استخدام أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">إذا أصبحت الرؤية لديك غير واضحة بشكل مؤقت بعد استخدام عقار توبراديكس، فلا تمارس القيادة أو تستخدم الآلات حتى تتضح الرؤية لديك مرة أخرى.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم عقار توبراديكس بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. يجب مراجعة طبيبك أو الصيدلي إذا لم تكن متأكدًّا من كيفية الاستخدام.</p><p dir="RTL">سيخبرك طبيبك بالمدة التي يجب عليك استخدام عقار توبراديكس خلالها. <strong>لا توقف العلاج مبكرًا</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا لم تتحسن الأعراض لديك أو تفاقمت أو عادت فجأة، فيُرجى استشارة طبيبك.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الموصى بها في البالغين والأطفال من عمر عامين فأكثر:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع 1 إلى 1.5 سم &quot;شريط&quot; من المرهم في عينك، حتى 3 أو 4 مرات يوميًّا.&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن استخدام عقار توبراديكس مرهم للعين عند النوم، بينما يمكن استخدام قطرات العين خلال النهار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات الاستخدام:</strong></p><p dir="RTL"><img alt="" width="622" height="200" src="data:image/png;base64,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" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اغسل يديك</strong> قبل استخدام عقار توبراديكس.</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اجلس أمام مرآة حتى تتمكن من رؤية ما تقوم بفعله.</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدر غطاء الأنبوب.</p><p dir="RTL">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تأكد من عدم ملامسة طرف الأنبوب لأي شيء آخر</strong>، إذ قد يلوث هذا المحتويات.</p><p dir="RTL">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بإمالة رأسك إلى الخلف.</p><p dir="RTL">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسحب الجفن السفلي للعين المصابة بإصبعك حتى يكون هناك &quot;جيب&quot; بين الجفن والعين (الصورة 1). يجب وضع شريط المرهم هنا.</p><p dir="RTL">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اجلب طرف الأنبوب بالقرب من عينك. استخدم المرآة إذا كان ذلك سيُساعدك.</p><p dir="RTL">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تلمس عينك أو جفنك أو المناطق المحيطة بهما أو الأسطح الأخرى بطرف الأنبوب.</p><p dir="RTL">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضغط برفق على الأنبوب لإخراج المرهم منه إلى داخل &quot;الجيب&quot; (صورة 2).</p><p dir="RTL">10. <strong>أغلق عينك لبضع ثوان </strong>بعد وضع المرهم في عينك (صورة 3).</p><p dir="RTL">11. كرر الخطوات من 6 إلى 10 في العين الأخرى، إذا اقتضى الأمر. أغلق غطاء الأنبوب بإحكام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استخدمت كمية أكثر مما يجب من عقار توبراديكس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وضعت كمية أكثر من اللازم من عقار توبراديكس <strong>داخل عينك،</strong> فاشطفه من عينك بماء فاتر. لا تضع المزيد من المرهم حتى حلول موعد جرعتك التَّالية المُعتادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا <strong>ابتلعت</strong> عقار توبراديكس بطريق الخطأ، فاطلب المشورة من طبيبك أو الصيدلي الخاص بك فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت استخدام عقار توبراديكس</strong></p><p dir="RTL">استخدم الجرعة التي أغفلتها في أسرع وقت ممكن. <strong>ومع ذلك، لا تستخدم جرعة مضاعفة لتعويض الجرعة التي نسيتها.</strong>&nbsp; إذا كان قد اقترب موعد الجرعة التَّالية، فتجاوز الجرعة التي أغفلتها واستمر في تلقي الجرعات بشكل منتظم وفقًا لجدولك المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام عقار توبراديكس</strong></p><p dir="RTL">قد يحدث تفاقم للالتهاب أو العدوى لديك إذا قمت بإيقاف العلاج <strong>مبكرًا.</strong> <strong>لا تتوقف فجأة عن استخدام هذا المنتج بدون استشارة طبيبك.</strong> قد يرغب طبيبك في خفض الكمية التي تستخدمها تدريجيًّا؛ وذلك لخفض فرصة الإصابة بالآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب عقار توبراديكس آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم تصنيف الآثار الجانبية وفقًا لمعدل تكرار حدوثها: شائعة جدًّا: تُؤثر في أكثر من مريض واحد من بين كل 10 مرضى، &quot;<strong>شائعة</strong>&quot;: تُؤثر في مريض واحد إلى 10 في كل 100 مريض، <strong>&quot;غير شائعة&quot;:</strong> تُؤثر في مريض واحد إلى 10 في كل 1,000 مريض، <strong>&quot;نادرة&quot;:</strong> تُؤثر في مريض واحد إلى 10 في كل 10,000 مريض، <strong>&quot;نادرة جدًّا&quot;:</strong> تُؤثر في أقل من مريض واحد في كل 10,000 مريض و<strong>&quot;غير معروفة&quot;:</strong> لا يمكن تقدير معدلات التكرار من واقع البيانات المتاحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن استخدام هذا الدَّواء واستشر طبيبك إذا كنت تعاني من تفاعلات فرط حساسية</strong>، مثل: حكة بالجفن، أو تورم بالعين أو احمرار بالعين.<strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لُوحظت الآثار الجانبية التَّالية مع عقار توبراديكس:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>اضطرابات العين:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غير شائعة:</strong> ارتفاع ضغط العين -ألم بالعين -حكة بالعين -شعور بعدم الراحة بالعين -تهيُّج بالعين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نادرة:</strong> التهاب العين -حساسية بالعين -عدم وضوح الرؤية -جفاف العين -احمرار العين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غير معروفة:</strong> تورم بجفن العين -احمرار بجفن العين -اتساع حدقة العين -زيادة إفراز الدُّموع -التهاب القرنية التقرحي.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تفاعلات في مناطق أخرى من جسمك:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نادرة:</strong> مذاق سيء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غير معروفة:</strong>&nbsp; تفاعلات حساسية شديدة (فرط الحساسية)- دوخة- صداع- غثيان- شعور بالانزعاج في البطن- تفاعلات جلدية خطيرة (احمرار متعدد الأشكال)- تورم بالوجه- حكة- احمرار الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المرجح وجود تأثيرات في أجزاء أخرى بجسمك لأنَّ جرعة العين هي أقل بكثير من الجرعة المستخدمة عن طريق الفم أو عن طريق الحقن، ولكن يمكن لبعض الأدوية أن تصل إلى مجرى الدَّم لديك. من الممكن أن تسبب الأمينُوجْليكُوزيدات التي يتم إعطاؤها عن طريق الفم أو عن طريق الحقن ضررًا بالكُلى أو الأعصاب في الأذن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي عقار توبراديكس على كلٍّ من توبراميسين وديكساميثازون. تمت ملاحظة الآثار الجانبية التَّالية مع المكونات الفردية لهذا الدَّواء أثناء الاستخدام في العين، وقد يحدث مع استخدام عقار توبراديكس.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>اضطرابات العين: </strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>غير شائعة: </strong>تهيج العين -احمرار العين -عدم وضوح الرؤية -ارتفاع ضغط العين.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نادرة: </strong>عدوى بالعين -انخفاض أو اضطراب الرؤية -الجلوكوما (المياه الزرقاء) -المياه البيضاء -تورم بجفن العين -حكة بجفن العين -ألم بالعين -تلف بالعصب البصري.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نادرة جدًّا: </strong>انثقاب مقلة العين.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>غير معروفة:</strong>عدم وضوح الرؤية</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تفاعلات في مناطق أخرى من جسمك:</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>غير شائعة: </strong>فرط الحساسية.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نادرة: </strong>ضعف الشفاء.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نادرة جدًّا: </strong>كبت الغدة الكظرية.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>غير معروفة:</strong> مشاكل بالهرمونات: نمو شعر الجسم بكثافة (خاصَّة في السيدات)، ضعف العضلات والهزال، علامات تمدد أرجوانية اللون على جلد الجسم، ارتفاع ضغط الدَّم، غياب دورات الحيض أو عدم انتظامها، تغيرات في مستويات البروتين والكالسيوم في جسمك، تضاؤل النمو في الأطفال والمراهقين وتورم وزيادة وزن الجسم والوجه (تسمى &#39;متلازمة كوشينج&#39;) (انظر القسم 2، &quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبح أيٌّ من الآثار الجانبية خطيرًا، أو إذا لاحظت أية آثار جانبية غير الواردة في هذه النَّشرة، فيُرجى إبلاغ الطبيب أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدًا عن متناول ورؤية الأطفال.</p><p dir="RTL">لا تقم بالتَّخزين في درجة حرارة تتعدى 25 درجة مئوية. لا تعرضه للتبريد.</p><p dir="RTL"><strong>لا تستخدم عقار توبراديكس لمدة أطول من 4 أسابيع بعد فتحه لأول مرة.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم عقار توبراديكس بعد انتهاء تاريخ الصلاحية المدون على الأنبوب والعبوة الكرتونية بعد كلمة &ldquo;EXP&rdquo;.&nbsp; يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يجب عدم التَّخلص من الأدوية عن طريق مياه الصرف أو مع المخالفات المنزلية.&nbsp; اسأل الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد بحاجة إليها. ستُساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي توبراميسين (3 مجم/جم) وديكساميثازون (1 مجم/جم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي كلوروبيوتانول اللا مائي، البارافين السائل والبارافين الأبيض النَّاعم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار توبراديكس مرهم للعين عبارة عن مرهم متجانس ذي لون أبيض يميل إلى الاصفرار، متوفر في أنبوب ألمونيوم 3.5 جم مزود بغطاء لولبي.</p><p dir="RTL"><br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تم اعتماد هذه النشرة من قبل السلطات الصحية في بلجيكا في: 08/2019م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TOBRADEX 3 mg/g + 1 mg/g eye ointment
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 g ointment contains 3 mg tobramycin and 1 mg dexamethasone.

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye ointment: white to off-white, homogeneous ointment
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For ocular steroid-responsive<strong> inflammatory</strong> conditions for which a corticosteroid is indicated and where bacterial ocular infection, or a risk of bacterial ocular infection, exists, due to tobramycin-responsive microorganisms resistant to most of the other antibiotics, especially <em>Pseudomonas aeruginosa,</em> in adults and children aged 2 years and older. See section 5.1.</p><p>&nbsp;</p><p>Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the eye where the inherent risk of steroid use in certain infective conjunctivites is accepted to obtain a decrease in oedema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical agents, radiation, thermal burns, or penetration of foreign bodies (considering the contraindications).</p><p>&nbsp;</p><p>Corticosteroids in eye ointment should be prescribed only after ocular examination.</p><p>&nbsp;</p><p>Please consider the official recommendations regarding the adequate use of antibiotics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Eye ointment:</strong></p><p><u>Posology</u></p><p>Apply a small amount (1 to 1.5 cm) into the conjunctival sac up to 3 or 4 times daily, or use adjunctively with the eye drops during the day and the eye ointment at bedtime.</p><p>Gently closing the eyelid and nasolacrimal occlusion after instillation is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic side effects.</p><p>&nbsp;</p><p>In case of concomitant therapy with other topical ocular medicinal products, an interval of 5 minutes should be allowed between successive applications. Eye ointments should be administered last.(see section 4.5).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>TOBRADEX eye ointment may be used in children 2 years of age and older at the same dose as in adults. Currently available data is described in section 5.1. The safety and efficacy in children younger than 2 years of age have not been established, and no data are available.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For ocular use.</p><p>To prevent contamination of the tube tip and ointment, care must be taken not to touch the eyelids, surrounding areas, or other surfaces with the tube tip. Keep the tube tightly closed when not in use.</p><p>1.&nbsp;&nbsp;&nbsp; Tilt your head back.</p><p>2.&nbsp;&nbsp;&nbsp; Place a finger on your cheek just below your eye and gently pull down until a &quot;V&quot; pocket is formed between your eye and your lower eyelid.</p><p>3.&nbsp;&nbsp;&nbsp; Place a small amount (1 to 1.5 cm) of TOBRADEX eye ointment in the &quot;V&quot; pocket. Do not let the tip of the tube touch your eye.</p><p>4.&nbsp;&nbsp;&nbsp; Look downward for a few moments before closing your eye.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substances or to any of the excipients.
•	Hypersensitivity to aminoglycosides
•	Herpes simplex keratitis. 
•	Vaccinia, varicella, and other viral infection of cornea or conjunctiva (except herpes zoster keratitis).
•	Fungal diseases of ocular structures or untreated parasitic eye infections.
•	Mycobacterial ocular infections.
•	Infections or injuries limited to the superficial corneal epithelium.
•	TOBRADEX should not be used following an uncomplicated removal of a foreign body from the cornea.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For ocular use only. Not for injection or ingestion.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The initial prescription and renewal thereof should be made only after examination of the patient with the aid of magnification such as slit-lamp biomicroscopy and, if necessary, fluorescein staining.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensitivity to topically administered aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticarial, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If hypersensitivity develops during use of this medicine, treatment should be discontinued.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cross-hypersensitivity to other aminoglycosides can occur, and the possibility that patients who became sensitized to topical tobramycin may also be sensitive to other topical and/or systemic aminoglycosides should be considered.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious adverse reactions including neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Caution is advised when TOBRADEX is used concomitantly with systemic aminoglycoside (See Section 4.8).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caution should be exercised when prescribing TOBRADEX to patients with known or suspected neuromuscular disorders such as myasthenia gravis or Parkinson&rsquo;s disease. Aminoglycosides may aggravate muscle weakness because of their potential effect on neuromuscular function.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive and/or prolonged use of topical ophthalmic corticosteroids increases the risk of ocular complications and could cause systemic side effects. If the inflammatory condition does not improve within a reasonable period during the course of the therapy, other forms of therapy should be instituted to reduce these risks.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Topical application of corticosteroids may be accompanied by a decrease in the urinary secretion of cortisol as well as a decrease in plasma cortisol concentration.&nbsp; Corticosteroids have been associated with hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing&rsquo;s Syndrome, and a decreased rate of growth in children, especially with high-dose or long-term treatment.</p><p>&nbsp;</p><p>Prolonged use of ophthalmic corticosteroids may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, reduced visual acuity and visual field defects, and posterior subcapsular cataract formation. In patients receiving ophthalmic corticosteroid therapy for 10 days or longer, intraocular pressure should be checked routinely and frequently, even though it may be difficult in children and uncooperative patients. This is especially important in paediatric patients, as the risk of corticosteroid-induced ocular hypertension may be greater in children and may occur earlier than in adults. Patients with a family or personal history of glaucoma have a higher risk of a corticosteroid-induced rise in intraocular pressure. Patients with glaucoma should be monitored weekly.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cushing&rsquo;s syndrome and/or adrenal suppression associated with systemic absorption of ocular dexamethasone may occur after intensive or long-term continuous therapy in predisposed patients, including children and patients treated with CYP3A4 inhibitors (including ritonavir and cobicistat). In these cases, treatment should be progressively discontinued.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged use of corticosteroids may also reduce resistance to and aid in the establishment of bacterial, viral, fungal or parasitic infections and mask the clinical signs of infection, preventing recognition of ineffectiveness of the antibiotic. TOBRADEX should therefore only be used in acute purulent infections of the eye when treatment with a steroid/anti-infective combination product is medically necessary.&nbsp; Fungal infection should be suspected in patients with persistent corneal ulceration. If fungal infection occurs, corticosteroids therapy should be discontinued.</p><p>&nbsp;</p><p>The use of antibiotics such as tobramycin may also result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ocular herpes simplex has occurred in patients under systemic or local corticosteroid therapy for other conditions. Using corticosteroid medication in the treatment of herpes simplex other than epithelial herpes simplex keratitis, in which it is contraindicated, requires great caution; periodic slit-lamp microscopy is essential.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Topical ophthalmic corticosteroids may slow corneal wound healing. Topical NSAIDs are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. (See section 4.5).</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment should not be discontinued prematurely as a flare-up of the infectious or inflammatory condition may occur with the sudden interruption of a treatment with antibiotics or high doses of corticosteroids, respectively.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The risk of corticosteroid-induced raised intraocular pressure and/or cataract formation is increased in predisposed patients (e.g. diabetes).</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact lens wear is not recommended during treatment of an ocular infection or inflammation.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>It is advisable that the intraocular pressure be checked frequently. This is especially important in paediatric patients receiving dexamethasone-containing products, as the risk of steroid-induced ocular hypertension may be greater in children below 6 years of age and may occur earlier than a steroid response in adults. The frequency and duration of treatment should be carefully considered, and the IOP should be monitored from the outset of treatment, recognizing the risk for earlier and greater steroid-induced IOP increases in the paediatric patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No interaction studies have been performed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interactions have been reported with systemic administration of the individual components. Concomitant use of topical steroids and topical NSAIDs may increase the potential for corneal healing Nevertheless, systemic absorption of ophthalmic tobramycin and dexamethasone is low and the chance of any interaction is minimal. &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When using pupil-dilating eye drops (atropine and other anticholinergic substances), which may cause elevation of intraocular pressure, concomitant use of TOBRADEX may lead to an additional elevation of intraocular pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients treated with ritonavir or other strong CYP3A4 inhibitors, plasma concentrations of dexamethasone may be increased (See Section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CYP3A4 inhibitors (including ritonavir and cobicistat): may decrease dexamethasone clearance resulting in increased effects and adrenal suppression/Cushing&rsquo;s syndrome. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid effects.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If more than one eye preparation is being used, the products must be administered at least 5 minutes apart. Eye ointments should be administered last.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong></p><p>Studies have not been conducted to evaluate the effect of tobramycin on human or animal</p><p>fertility. There is limited clinical data to evaluate the effect of dexamethasone on male or</p><p>female fertility. Dexamethasone was free of adverse effects on fertility in a chorionic</p><p>gonadotropin primed rat model.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy</strong></p><p>There are no or limited amount of data from the topical ocular use of tobramycin and dexamethasone in pregnant women. Tobramycin does cross the placenta into the fetus after intravenous dosing in pregnant women. Tobramycin is not expected to cause ototoxicity from <em>in utero </em>exposure. Prolonged or repeated corticoid use during pregnancy has been associated with an increased risk of intra-uterine growth retardation. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism. Studies in animals have shown reproductive toxicity after topical administration of dexamethasone and after systemic administration of dexamethasone and tobramycin (see section 5.3).</p><p>TOBRADEX is not recommended during pregnancy.</p><p>&nbsp;</p><p><strong>Breastfeeding</strong></p><p>Tobramycin is excreted in human milk after systemic administration. No data is available on</p><p>the passage of dexamethasone into human breast milk. It is unknown whether tobramycin and</p><p>dexamethasone are excreted in human milk following topical ocular administration. It is not</p><p>likely that the amount of Tobramycin and Dexamethasone would be detectable in human</p><p>milk or be capable of producing clinical effects in the infant following topical use of the</p><p>product.</p><p>A risk to the suckling child cannot be excluded. A decision must be made whether to</p><p>discontinue breast-feeding or to discontinue/abstain from therapy taking into account the</p><p>benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TOBRADEX has no or negligible influence on the ability to drive and use machines. However, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at application, the patient must wait until the vision clears before driving or using machines.</p><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p>No serious ophthalmic adverse events related to TOBRADEX were reported in clinical studies. The most frequently reported treatment-related adverse reactions were eye pain, intraocular pressure increased, eye irritation, and eye pruritus occurring in less than 1% of patients.</p><p>&nbsp;</p><p><strong>Tabulated summary of adverse reactions</strong></p><p>The following adverse reactions are classified according to the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), or not known (cannot be estimated from the available data). Within each frequency-grouping, adverse reactions are presented in order of decreasing seriousness. The adverse reactions have been observed during clinical trials and post-marketing experience with TOBRADEX.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Classification</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><em>Not known: </em>hypersensitivity, anaphylactic reaction,</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><em>Not known: </em>dizziness,<em> </em>headache</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p><em>Uncommon</em>: intraocular pressure increased, eye pain, eye pruritus, ocular discomfort, eye irritation</p><p><em>Rare: </em>keratitis, eye allergy, vision blurred, dry eye, ocular hyperaemia</p><p><em>Not known: </em>eyelid oedema, erythema of eyelid, mydriasis, lacrimation increased , ulcerative keratitis</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p><em>Rare: </em>dysgeusia</p><p><em>Not known: </em>nausea, abdominal discomfort</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><em>Not known: </em>rash, swelling face, pruritus, erythema multiforme</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Description of selected adverse reactions</strong></p><p>Topical ophthalmic corticosteroid use may result in increased intraocular pressure with damage to the optic nerve, reduced visual acuity and visual field defect, and posterior subcapsular cataract formation (See Section 4.4. Special warnings and precautions for use).</p><p>&nbsp;</p><p>Due to the steroid component, in diseases causing thinning of the cornea or sclera there is a higher risk for perforation especially after longer treatment (See Section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p>The development of secondary infection has occurred after use of combinations containing steroids and antimicrobials. Fungal infections of the cornea are particularly prone to develop coincidentally with long term applications of steroids. The possibility of fungal invasion must be considered in any persistent corneal ulceration where steroid treatment has been used. Secondary ocular infection following suppression of host responses also occurs. (See Section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p>When administered systemically, tobramycin may induce renal, vestibular and auditory nerve toxicity, especially in patients receiving high doses or prolonged treatment. Doses recommended for ocular administration are significantly lower than those used systemically, and these systemic effects are extremely unlikely with TOBRADEX (See Section 4.4 Special warnings and precautions for use).</p><p>Sensitivity to topically administered aminoglycosides may occur in some patients (See Section 4.4).</p><p>&nbsp;</p><p>Undesirable effects have occurred with steroid/antibiotic combination drugs which can usually be attributed to either the steroid component or the antibiotic component. The following adverse effects have been reported following use of topical ophthalmic dexamethasone or tobramycin.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dexamethasone</strong></p></td><td style="vertical-align:top"><p><strong>Tobramycin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Classification</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p><em>Rare: </em>eye infection (exacerbation or secondary)</p></td><td style="vertical-align:top"><p><em>Very rare: </em>eye infection (secondary)</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p><em>Very rare: </em>adrenal suppression</p><p><em>Unknown: </em>Cushing&#39;s syndrome, adrenal suppression (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p><em>Rare:</em> visual acuity reduced, glaucoma, visual field defect, cataract subcapsular</p><p><em>Unknown</em>: Vision, blurred (see also section 4.4)</p></td><td style="vertical-align:top"><p><em>Uncommon: </em>eye irritation, ocular hyperaemia, vision blurred</p><p><em>Rare: </em>eyelid oedema, eyelids pruritus, eye pain (periorbital)</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p><em>Rare:</em> impaired healing</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p><em>Uncommon:</em> intraocular pressure increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p><em>Rare: </em>optic nerve injury</p><p><em>Very rare: </em>corneal perforation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><em>Uncommon: </em>hypersensitivity (local)</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><em>Uncommon: </em>erythema (periorbital)</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A topical overdose is not likely to occur or to be associated with toxicity.</p><p>A topical overdose of TOBRADEX can be flushed from the eye(s) with lukewarm water.</p><p>Due to the characteristics of this preparation, no toxic effects are to be expected with an ocular overdose of this product, or in the event of accidental ingestion of the contents of one bottle or tube. Treatment of an accidental ingestion is symptomatic and supportive.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: corticosteroids and anti-infectives in combination</p><p>ATC code: S 01 CA 01</p><p>&nbsp;</p><p><u>Mode of Action</u></p><p>The preparation contains tobramycin, a rapidly bactericidal aminoglycoside antibiotic.&nbsp; It exerts its primary effect on bacterial cells by inhibiting polypeptide assembly and synthesis on the ribosome.</p><p>&nbsp;</p><p><u>Mechanism of resistance</u></p><p>Resistance to tobramycin occurs by several different mechanisms including (1) alterations of the ribosomal subunit within the bacterial cell; (2) interference with the transport of tobramycin into the cell, and (3) inactivation of tobramycin by an array of adenylylating, phosphorylating, and acetylating enzymes. Genetic information for production of inactivating enzymes may be carried on the bacterial chromosome or on plasmids. Cross resistance to other aminoglycosides may occur.</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>The breakpoints and the <em>in vitro</em> spectrum as mentioned below are based on systemic use. These breakpoints might not be applicable on topical ocular use of the medicinal product as higher concentrations are obtained locally and the local physical/chemical circumstances can influence the activity of the product on the site of administration.&nbsp; In accordance with EUCAST, the following breakpoints are defined for tobramycin:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Enterobacteriaceae</em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; S &le; 2 mg/l, R &gt; 4 mg/l</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pseudomonas spp.</em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; S &le; 4 mg/l, R &gt; 4 mg/l</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Staphylococcus spp.</em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; S &le; 1 mg/l, R &gt; 1 mg/l</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not species-related&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; S &le; 2 mg/l, R &gt; 4 mg/l</p><p><u>&nbsp;</u></p><p><u>PK/PD relationschip</u></p><p>&nbsp;</p><p>A specific PK/PD relationship has not been established for Tobradex. Dexamethasone has</p><p>demonstrated dose-independent pharmacokinetics in published animal studies.</p><p>&nbsp;</p><p>Published in vitro and in vivo studies have shown that tobramycin features a prolonged postantibiotic</p><p>effect, which effectively suppresses bacterial growth despite low serum</p><p>concentrations. Systemic administration studies of tobramycin have reported higher</p><p>maximum concentrations with once daily compared to multiple daily dosing regimens.</p><p>However, the weight of current evidence suggests that once daily systemic dosing is equally</p><p>as efficacious as multiple-daily dosing. Tobramycin exhibits a concentration-dependent</p><p>antimicrobial kill and greater efficacy with increasing levels of antibiotic above the MIC or</p><p>minimum bactericidal concentration (MBC).</p><p>&nbsp;</p><p><u>Clinical efficacy against specific pathogens</u></p><p>&nbsp;</p><p>The information listed below gives only an approximate guidance on probabilities whether microorganisms will be susceptible to tobramycin in<sup> </sup>this medicine. Bacterial species that have been recovered from external infections of the eye such as observed in conjunctivitis are presented here.</p><p>&nbsp;</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of tobramycin in at least some types of infections is questionable.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>COMMONLY SUSCEPTIBLE SPECIES </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic Gram-positive microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Corynebacterium </em>species</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em>(methicillin susceptible)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic Gram-negative microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacter cloacae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Klebsiella oxytoca</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria meningitidis </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas aeruginosa</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Serratia </em><em>marescens</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Antibacterial activity against other relevant pathogens</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>SPECIES FOR WHICH ACQUIRED RESISTANCE MIGHT BE A PROBLEM</strong></p><p><strong>&nbsp;</strong></p><p><strong>Aerobic Gram-positive microorganisms</strong></p><p><em>Corynebacterium diphtheriae</em></p><p><em>Staphylococcus aureus </em>(methicillin resistant)</p><p><em>Staphylococcus, </em>other coagulase-negative spp. (methicillin resistant)</p><p><strong>&nbsp;</strong></p><p><strong>Aerobic Gram-negative microorganisms</strong></p><p><em>Neisseria gonorrhoeae</em></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>INHERENTLY RESISTANT ORGANISMS</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic Gram-positive microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pyogenes </em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic Gram-negative microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anaerobic Bacteria</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Propionibacterium acnes</em></p><p><em>&nbsp;</em></p><p><strong>Other</strong></p><p><em>Chlamydia trachomatis</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Dexamethasone is a moderately powerful corticosteroid, which has a good penetration in the ocular tissue. Cortico&shy;steroids have an anti‑inflammatory as well as a vasoconstrictive effect. They suppress the inflammatory response and symptoms in various disorders without basically curing these disorders.</p><p>&nbsp;</p><p><u>Data from clinical studies</u></p><p>&nbsp;</p><p>Cumulative safety data from clinical studies are presented in Section 4.8.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of TOBRADEX eye drops and eye ointment in children have been established by broad clinical experience, but only limited data are available. In a clinical study of TOBRADEX suspension for the treatment of bacterial conjunctivitis, 29 paediatric patients, ranging in age from 1 to 17 years, were treated with 1 or 2 drops of TOBRADEX every 4 or 6 hours for 5 or 7 days. In this study, differences in the safety profile between adult and paediatric patients were not observed. See section 4.2 and 4.4 for more information on pediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dexamethasone</u></p><p>The studies conducted with TOBRADEX eye drops, suspension have demonstrated that the systemic exposure to dexamethasone is low after topical eye use. The maximum plasma concentrations ranged between 220-888 pg/ml (medium values 555 &plusmn; 217 pg/ml) after the instillation of one drop of TOBRADEX in each eye, 4 times a day, for two consecutive days.</p><p>&nbsp;</p><p>Dexamethasone is eliminated through the metabolism. Approximate 60% of the dose is recovered in urine as 6-&beta;-hydroxydexamethasone. Unmodified dexamethasone is not recovered in urine. The plasma half-life through elimination is relatively short, 3-4 hours. Dexamethasone binds to the serum albumin approximately 77-84%. The clearance varies from 0.111 to 0.225 l/hour and kg, and the distribution volume varies from 0.576 to 1.15 l/kg. The oral bioavailability of dexamethasone is approximately 70%.</p><p>&nbsp;</p><p><u>Tobramycin</u></p><p>The studies conducted on TOBRADEX eye drops, suspension have shown that the systemic exposure to tobramycin is low after topical ocular use. The plasma concentrations of tobramycin could not be determined in 9 of 12 patients to whom one drop of TOBRADEX has been administered, 4 times a day, for two consecutive days. The highest plasma concentration that could be measured was 0.25 &mu;g/ml, a value that is 8 times smaller than the 2 &mu;g/ml concentration known to be under the threshold associated with the risk of nephrotoxicity.</p><p>&nbsp;</p><p>Tobramycin is rapidly excreted in large quantities in the urine through glomerular filtration, mainly unmodified. The plasma half-life is approx. 2 hours, with a 0.04 l/hour and kg clearance and a distribution volume of 0.26 l/kg. Binding of tobramycin to plasma albumin is low, less than10%. The oral bioavailability is low (&lt;1%).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects in conventional non-clinical studies of repeated dose toxicity were observed only at exposures considered sufficiently in excess of the maximum human exposure after topical application, indicating little relevance to clinical use.</p><p>&nbsp;</p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of genotoxicity. No studies have been conducted to evaluate the carcinogenic potential of dexamethasone.</p><p>Tobramycin crosses the placenta into the foetal circulation and amniotic fluid. Animal studies with maternal systemic administration of high doses of tobramycin during organogenesis have been reported to result in renal toxicity in foetuses. Other studies performed in rats and rabbits with tobramycin at doses up to 100 mg/kg/day parenterally (&gt; 400-times the maximum clinical dose) revealed no evidence of&nbsp; harm to the foetus.</p><p>&nbsp;</p><p>Corticosteroids have been found to be teratogenic in animal studies. Ocular administration of a 0.1% dexamethasone preparation to pregnant rabbits resulted in increased incidences of foetal anomalies. Foetal growth retardation and increased mortality rates have been observed in rats with chronic dexamethasone therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Eye ointment:</strong></p><p>Chlorobutanol, anhydrous</p><p>Liquid paraffin</p><p>White soft paraffin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific incompatibility studies with TOBRADEX have been undertaken.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
Discard 4 weeks after first opening.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Eye ointment: </strong>Do not store above 25&deg;C. Do not refrigerate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><strong>Eye ointment: </strong>Tobradex 3 mg/g + 1 mg/g eye ointment is a white to off-white homogeneous ointment, supplied in an aluminum tube of 3,5 g with screw cap.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20/08/2019 by Belgian health authorities
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>